insights_auto
Kāpēc uzņēmuma G1SK34 akciju cena ir pieaugusi 4,02%?
Atklājiet vairāk iespējuchevron_right
G1SK34:BVMF
GSK
50,50 R$
arrow_upward
+4,02%(+1,95) 1 d.
16. okt., 16:56:00 GMT-3 · BRL
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: G1SK34…
Atvērt
50,10 R$
Augsta
50,75 R$
Zema
50,10 R$
Tirgus kapitalizācija
100,21 mljrd.
Vid. apjoms
214,00
Apjoms
165,00
Augstākā 52 ned.
63,24 R$
Zemākā 52 ned.
46,15 R$
Apgrozībā esošās akcijas
4,32 mljrd.
Darbinieku skaits
67 tūkst.
Atvērt
50,10 R$
Augsta
50,75 R$
Zema
50,10 R$
Tirgus kapitalizācija
100,21 mljrd.
Vid. apjoms
214,00
Apjoms
165,00
Augstākā 52 ned.
63,24 R$
Zemākā 52 ned.
46,15 R$
Apgrozībā esošās akcijas
4,32 mljrd.
Darbinieku skaits
67 tūkst.
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
The Globe and Mail
·
pirms 9 stundām
UBS Keeps Their Hold Rating on GlaxoSmithKline (GSK)
Traders Union
·
pirms 12 stundām
GSK shares technical analysis: Overbought conditions highlight reversal setup
JournalArta
·
pirms 19 stundām
GSK Stock Gains 2.89% on Thursday: Full Details
Yahoo Finance
·
pirms 1 dienas
Better Dividend Stock: Pfizer vs. GSK
Profils
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
Par “GSK”
ĢenerāldirektorsEmma Walmsley | Emma Walmsley
Darbinieki66,8 tūkst.
Dibināšanas datums2000. gada 27. dec.
Galvenais birojs-
Sektors-
Tīmekļa vietnegsk.com